The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Aurora-A Abrogation of p53 DNA Binding and Transactivation Activity by Phosphorylation of Serine 215
Open accessAbstract
The tumor suppressor p53 is important in the decision to either arrest cell cycle progression or induce apoptosis in response to a variety of stimuli. p53 posttranslational modifications and association with other proteins have been implicated in the regulation of its stability and transactivation activity. Here we show that p53 is phosphorylated by the mitotic kinase Aurora-A at serine 215. Unlike most identified phosphorylation sites of p53 that positively associate with p53 function (Brooks, C. L., and Gu, W. (2003) Curr. Opin. Cell Biol. 15, 164-171), the phosphorylation of p53 by Aurora-A at Ser-215 abrogates p53 DNA binding and transactivation activity. Downstream target genes of p53, such as p21Cip/WAF1 and PTEN, were inhibited by Aurora-A in a Ser-215 phosphorylation-dependent manner (i.e. phosphomimic p53-S215D lost and non-phosphorylatable p53-S215A retained normal p53 function). As a result, Aurora-A overrides the apoptosis and cell cycle arrest induced by cisplatin and gamma-irradiation, respectively. However, the effect of Aurora-A on p53 DNA binding and transactivation activity was not affected by phosphorylation of Ser-315, a recently identified Aurora-A phosphorylation site of p53 (Katayama, H., Sasai, K., Kawai, H., Yuan, Z. M., Bondaruk, J., Suzuki, F., Fujii, S., Arlinghaus, R. B., Czerniak, B. A., and Sen, S. (2004) Nat. Genet. 36, 55-62). Our data indicate that phosphorylation of p53 at Ser-215 by Aurora-A is a major mechanism to inactivate p53 and can provide a molecular insight for Aurora-A function.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
3 retracted
Yuan, Z., Feldman, R. I., Sun, M., Olashaw, N., Coppola, D., Sussman, G. E., Shelley, S. A., Nicosia, S. V., & Cheng, J. Q. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m203636200 · Cited by 57
Self-citationRetractedPositive Feedback Regulation between Akt2 and MyoD during Muscle Differentiation
Kaneko, S., Feldman, R. I., Yu, L., Wu, Z., Gritsko, T. M., Shelley, S. A., Nicosia, S. V., Nobori, T., & Cheng, J. Q. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m201733200 · Cited by 55
Self-citationRetractedKaneko, S., Feldman, R. I., Yu, L., Wu, Z., Gritsko, T. M., Shelley, S. A., Nicosia, S. V., Nobori, T., & Cheng, J. Q. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.a116.201733 · Cited by 53
Self-citationRetractedCurrent protocols in molecular biology
Sargent, T. (1988) · Analytical Biochemistry · doi:10.1016/0003-2697(88)90147-9 · Cited by 7,205
Tumour amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy and transformation
Zhou, H., Kuang, J., Zhong, L., Kuo, W.-L., Gray, J., Sahin, A., Brinkley, B., & Sen, S. (1998) · Nature Genetics · doi:10.1038/2496 · Cited by 1,276
A role for ATR in the DNA damage-induced phosphorylation of p53
Tibbetts, R. S., Brumbaugh, K. M., Williams, J. M., Sarkaria, J. N., Cliby, W. A., Shieh, S.-Y., Taya, Y., Prives, C., & Abraham, R. T. (1999) · Genes & Development · doi:10.1101/gad.13.2.152 · Cited by 1,046
Database of p53 gene somatic mutations in human tumors and cell lines.
Hollstein, M. C., Rice, K., Greenblatt, M. S., Soussi, T., Fuchs, R., Sørlie, T., Hovig, E. J., Smith‐Sørensen, B., Montesano, R., & Harris, C. C. (1994) · Europe PMC (PubMed Central) · Cited by 858
Abnormal Centrosome Amplification in the Absence of p53
Fukasawa, K., Choi, T., Kuriyama, R., Rulong, S., & Woude, G. F. V. (1996) · Science · doi:10.1126/science.271.5256.1744 · Cited by 797
Anand, S., Penrhyn-Lowe, S., & Venkitaraman, A. R. (2003) · Cancer Cell · doi:10.1016/s1535-6108(02)00235-0 · Cited by 631
Phosphorylation by aurora kinase A induces Mdm2-mediated destabilization and inhibition of p53
Katayama, H., Sasai, K., Kawai, H., Yuan, Z.-M., Bondaruk, J., Suzuki, F., Fujii, S., Arlinghaus, R. B., Czerniak, B. A., & Sen, S. (2004) · Nature Genetics · doi:10.1038/ng1279 · Cited by 588
Cited by
Regulating the p53 pathway: in vitro hypotheses, in vivo veritas
Toledo, F., & Wahl, G. M. (2006) · Nature reviews. Cancer · doi:10.1038/nrc2012 · Cited by 1,286
Kinase-targeted cancer therapies: progress, challenges and future directions
Bhullar, K. S., Lagarón, N. O., McGowan, E. M., Parmar, I., Jha, A., Hubbard, B. P., & Rupasinghe, H. P. V. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0804-2 · Cited by 1,245
Aurora-A — A guardian of poles
Marumoto, T., Zhang, D., & Saya, H. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1526 · Cited by 697
Roles of Aurora Kinases in Mitosis and Tumorigenesis
Fu, J., Bian, M., Jiang, Q., & Zhang, C. (2007) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-06-0208 · Cited by 614
Targeting AURKA in Cancer: molecular mechanisms and opportunities for Cancer therapy
Du, R., Huang, C., Liu, K., Li, X., & Dong, Z. (2021) · Molecular Cancer · doi:10.1186/s12943-020-01305-3 · Cited by 586
Aurora A kinase (AURKA) in normal and pathological cell division
Nikonova, A. S., Astsaturov, I., Serebriiskii, I. G., Dunbrack, R. L., & Golemis, E. A. (2013) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-012-1073-7 · Cited by 448
The Aurora kinase family in cell division and cancer
Vader, G., & Lens, S. M. A. (2008) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2008.07.003 · Cited by 417
The functional diversity of Aurora kinases: a comprehensive review
Willems, E., Dedobbeleer, M., Digregorio, M., Lombard, A., Lumapat, P. N., & Rogister, B. (2018) · Cell Division · doi:10.1186/s13008-018-0040-6 · Cited by 416
Aurora kinases: novel therapy targets in cancers
Tang, A., Gao, K., Chu, L., Zhang, R., Yang, J., & Zheng, J. (2017) · Oncotarget · doi:10.18632/oncotarget.14893 · Cited by 382
p53 and breast cancer, an update
Lacroix, M., Toillon, R.-A., & Leclercq, G. (2006) · Endocrine-Related Cancer · doi:10.1677/erc.1.01172 · Cited by 380
The aurora kinases in cell cycle and leukemia
Goldenson, B., & Crispino, J. D. (2015) · Oncogene · doi:10.1038/onc.2014.14 · Cited by 334
Mutant p53 in Cancer: Accumulation, Gain-of-Function, and Therapy
Yue, X., Zhao, Y., Xu, Y., Zheng, M., Feng, Z., & Hu, W. (2017) · Journal of Molecular Biology · doi:10.1016/j.jmb.2017.03.030 · Cited by 308
Manfredi, M. G., Ecsedy, J. A., Chakravarty, A., Silverman, L., Zhang, M., Hoar, K. M., Stroud, S. G., Chen, W., Shinde, V., Huck, J. J., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1536 · Cited by 300
Aurora‐A Kinase: A Potent Oncogene and Target for Cancer Therapy
Yan, M., Wang, C., He, B., Yang, M., Tong, M., Long, Z., Liu, B., Peng, F., Xu, L., Zhang, Y., et al. (2016) · Medicinal Research Reviews · doi:10.1002/med.21399 · Cited by 293
Self-citationRegulation of the p53 response and its relationship to cancer
Meek, D. W. (2015) · Biochemical Journal · doi:10.1042/bj20150517 · Cited by 288
Drugging MYCN through an Allosteric Transition in Aurora Kinase A
Gustafson, W. C., Meyerowitz, J. G., Nekritz, E. A., Chen, J., Benes, C., Charron, E., Simonds, E. F., Seeger, R., Matthay, K. K., Hertz, N. T., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.07.015 · Cited by 278
Self-citationAurora Kinases: New Targets for Cancer Therapy
Carvajal, R. D., Tse, A., & Schwartz, G. K. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1405 · Cited by 275
Aurora kinases, aneuploidy and cancer, a coincidence or a real link?
Giet, R., Petretti, C., & Prigent, C. (2005) · Trends in Cell Biology · doi:10.1016/j.tcb.2005.03.004 · Cited by 262
Wang, X., Zhou, Y.-X., Qiao, W., Tominaga, Y., Ouchi, M., Ouchi, T., & Deng, C.-X. (2006) · Oncogene · doi:10.1038/sj.onc.1209707 · Cited by 261
Komlodi-Pasztor, E., Sackett, D. L., & Fojo, A. T. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0999 · Cited by 227
Cammareri, P., Scopelliti, A., Todaro, M., Eterno, V., Francescangeli, F., Moyer, M. P., Agrusa, A., Dieli, F., Zeuner, A., & Stassi, G. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3953 · Cited by 159
AURKA is one of the downstream targets of MAPK1/ERK2 in pancreatic cancer
Furukawa, T., Kanai, N., Shiwaku, H. O., Soga, N., Uehara, A., & Horii, A. (2006) · Oncogene · doi:10.1038/sj.onc.1209494 · Cited by 135
Vilgelm, A. E., Pawlikowski, J. S., Liu, Y., Hawkins, O. E., Davis, T. A., Smith, J., Weller, K. P., Horton, L. W., McClain, C. M., Ayers, G. D., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-2405 · Cited by 115
Extensive Post-translational Modification of Active and Inactivated Forms of Endogenous p53
DeHart, C. J., Chahal, J. S., Flint, S. J., & Perlman, D. H. (2014) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m113.030254 · Cited by 70
Zhang, W., Xia, D., Li, Z., Zhou, T., Chen, T., Wu, Z., Zhou, W., Li, Z., Li, L., & Xu, J. (2019) · Cell Death & Disease · doi:10.1038/s41419-019-1855-z · Cited by 38
Cyclers’ kinases in cell division: from molecules to cancer therapy
Milletti, G., Colicchia, V., & Cecconi, F. (2023) · Cell Death & Differentiation · doi:10.1038/s41418-023-01196-z · Cited by 39
Phosphorylation and activation of androgen receptor by Aurora-A.
Shu, S.-K., Liu, Q., Coppola, D., & Cheng, J. Q. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.121129 · Cited by 38
Self-citationRetractedModelling the p53/p66Shc Aging Pathway in the Shortest Living Vertebrate Nothobranchius Furzeri
Priami, C., De Michele, G., Cotelli, F., Cellerino, A., Giorgio, M., Pelicci, P. G., & Migliaccio, E. (2015) · Aging and Disease · doi:10.14336/ad.2014.0228 · Cited by 16
Metadata
- Authors
- Liu, Q., Kaneko, S., Yang, L., Feldman, R. I., Nicosia, S. V., Chen, J., & Cheng, J. Q.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2004-12
- Volume
- 279
- Issue
- 50
- Pages
- 52175-52182
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2091312754
- Cited by
- 334
- References
- 38
- FWCI
- 7.05
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.